-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Acrivon Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2021 to Q2 2024.
- Acrivon Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$21.4M, a 38.1% decline year-over-year.
- Acrivon Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$76.3M, a 54.3% decline year-over-year.
- Acrivon Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$67.1M, a 105% decline from 2022.
- Acrivon Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$32.7M, a 102% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)